U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C34H33N3O5
Molecular Weight 563.6442
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ELACRIDAR

SMILES

COc1cccc2c1[nH]c3c(cccc3C(=O)Nc4ccc(cc4)CCN5CCc6cc(c(cc6C5)OC)OC)c2=O

InChI

InChIKey=OSFCMRGOZNQUSW-UHFFFAOYSA-N
InChI=1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38)

HIDE SMILES / InChI

Molecular Formula C34H33N3O5
Molecular Weight 563.6442
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://www.drugbank.ca/drugs/DB04881

Elacridar is an oral bioenhancer that targets multiple drug resistance in tumors. Elacridar is a strong and relatively specific inhibitor of P-gp and BCRP, two main efflux transporters. Development of elacridar is assumed to have been discontinued.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in mouse. Human data not available.

Approval Year

PubMed

PubMed

TitleDatePubMed
Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.
2003 Feb
Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.
2004 Jan 12
P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro.
2004 Jul
Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits.
2004 Jul
Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1.
2005 Aug
Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
2005 Jun 1
Comparison of drug efflux transport kinetics in various blood-brain barrier models.
2006 Jun
Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line.
2006 Oct
The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
2007 Jan
Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.
2007 Jul
P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
2007 Nov
Mechanisms underlying saturable intestinal absorption of metformin.
2008 Aug
Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse.
2008 Aug
N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk.
2008 Dec
P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
2008 Feb
Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.
2008 Feb
Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice.
2008 Jan
Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives.
2008 Jan 1
Role of P-glycoprotein and the intestine in the excretion of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] in rodents.
2008 Jun
Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.
2008 May
Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats.
2008 Nov
Development and characterisation of a new model of rat trophoblasts.
2009 Feb
Cross-functioning between the extraneuronal monoamine transporter and multidrug resistance protein 1 in the uptake of adrenaline and export of 5-(glutathion-S-yl)adrenaline in rat cardiomyocytes.
2009 Jan
Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.
2009 Mar
Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine.
2009 Oct
Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier.
2010 Jan
Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters.
2010 Oct
In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.
2010 Oct
In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption.
2010 Sep
Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
2010 Sep
Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux.
2012 May 1
Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).
2013 Dec
Patents

Sample Use Guides

The starting daily dose of GF120918 was 50 mg and was to be increased in subsequent cohorts until a steady state plasma level of 100 ng/ml was reached.
Route of Administration: Oral
In Caki-1 and ACHN cells, elacridar ( 2.5 μM) significantly inhibits the cell growth. The P-glycoprotein expression is found to be inhibited by 5 uM elacridar in all cell lines (786-O, ACHN, and Caki-1).
Substance Class Chemical
Created
by admin
on Sat Jun 26 06:24:01 UTC 2021
Edited
by admin
on Sat Jun 26 06:24:01 UTC 2021
Record UNII
N488540F94
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ELACRIDAR
INN   WHO-DD  
INN  
Official Name English
ELACRIDAR [INN]
Common Name English
4-ACRIDINECARBOXAMIDE, N-(4-(2-(3,4-DIHYDRO-6,7-DIMETHOXY-2(1H)-ISOQUINOLINYL)ETHYL)PHENYL)-9,10-DIHYDRO-5-METHOXY-9-OXO-
Systematic Name English
LY-335979
Code English
4'-(2-(3,4-DIHYDRO-6,7-DIMETHOXY-2(1H)-ISOQUINOLYL)ETHYL)-5-METHOXY-9-OXO-4-ACRIDANCARBOXANILIDE
Systematic Name English
ELACRIDAR [WHO-DD]
Common Name English
LY335979
Code English
Classification Tree Code System Code
NCI_THESAURUS C1744
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
Code System Code Type Description
CAS
143664-11-3
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
INN
7582
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
EVMPD
SUB06475MIG
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
ChEMBL
CHEMBL396298
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
NCI_THESAURUS
C73318
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
DRUG BANK
DB04881
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
FDA UNII
N488540F94
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
PUBCHEM
119373
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
MESH
C083501
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
EPA CompTox
143664-11-3
Created by admin on Sat Jun 26 06:24:01 UTC 2021 , Edited by admin on Sat Jun 26 06:24:01 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INDUCER
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY